Daewoong Pharmaceutical Acquires 3,136,869 Shares of Evolus Inc. in the U.S.
[Asia Economy Reporter Hyunseok Yoo] Daewoong Pharmaceutical announced on the 26th that it will acquire 3,136,869 shares of Evolus, a U.S. botulinum toxin sales company.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- Batteries Now Regarded as 'Strategic Resources'... Used Battery Act Passes Cabinet Meeting
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
The amount is 46.3 billion KRW, and the shareholding ratio after acquiring the shares will be 7.2%. The company explained, "This is the exercise of conversion rights according to the agreement contract between the two companies signed on the 23rd."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
